Event Brief
UPDATED Jun 1, 2026 at 9:00 PM ET
May 29, 2026 at 7:04 PM ET
Revolution Medicines pill daraxonrasib shows improved survival
By The BriefBrief
Trial results for daraxonrasib report 13.2-month overall survival versus 6.7 months with standard chemotherapy.
WHO: Revolution Medicines
WHAT: Clinical trial testing of daraxonrasib, a RAS inhibitor targeting KRAS, reports improved overall survival in pancreatic cancer.
WHEN: May 29, 2026 at 6:00 PM ET
WHERE: Location not specified
WHY: The trial data show higher overall survival for patients receiving daraxonrasib than for those on standard chemotherapy.
How this story developed (showing 3 of 3 earlier reports)
Reporting from 5 identified publishers across this event arc.
View all 5 publishers
Publishers represented across this event arc
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Construction milestone at Rome Yards housing project
Rome Yards
May 29, 2026 at 7:00 PM ET
Byron Donalds outlines career pathways from 6th grade
Byron Donalds
May 29, 2026 at 7:00 PM ET
Win free Snickers for a year with this name
Snickers
May 29, 2026 at 7:00 PM ET
Florida removes dozens of veterans from State Guard
Florida
May 29, 2026 at 7:00 PM ET
Page 17073 of 21417
Same format. Every time.
Continue reading — sign in or create a free account with
